Published in Immunology on July 01, 1996
The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol (2000) 0.95
Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol (1998) 0.94
Complement component C7 deficiency in a Spanish family. Clin Exp Immunol (2003) 0.90
Modulation of complement membrane attack by local C7 synthesis. Clin Exp Immunol (2000) 0.83
Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9. Immunology (2001) 0.83
Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit? Clin Exp Immunol (2003) 0.83
Complement component C7 deficiency in two Spanish families. Immunology (2004) 0.81
Complement components 2 and 7 (C2 and C7) gene polymorphisms are not major risk factors for SLE susceptibility in the Malaysian population. Rheumatol Int (2011) 0.76
DNA sequence variants in the G gamma-, A gamma-, delta- and beta-globin genes of man. Cell (1979) 15.74
Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) (1984) 4.62
Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement. J Infect Dis (1990) 1.26
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
Hereditary deficiency of the seventh component of complement. J Clin Invest (1975) 1.26
Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol (1991) 1.22
Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) (1993) 1.13
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet (1992) 1.06
Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa. J Infect Dis (1990) 1.01
Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol (1995) 1.00
Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol (1994) 0.98
Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. J Clin Invest (1995) 0.96
A novel protein polymorphism of human complement C7 detected by a monoclonal antibody. Immunogenetics (1992) 0.90
Immunological evaluation of late complement component-deficient individuals. Clin Immunol Immunopathol (1992) 0.87
Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement. Immunology (1994) 0.86
DNA polymorphisms of the complement C6 and C7 genes. Ann Hum Genet (1995) 0.85
Molecular basis of the complement C7 M/N polymorphism. A neutral amino acid substitution outside the epitope of the allospecific monoclonal antibody WU 4-15. J Immunol (1995) 0.85
The occurrence of precipitating antibodies in transfused Japanese patients with hereditary ninth component of complement deficiency and frequency of C9 deficiency. Transfusion (1987) 0.84
Terminal complement component deficiencies and rheumatic disease: development of a rheumatic syndrome and anticomplementary activity in a patient with complete C6 deficiency. Ann Rheum Dis (1985) 0.83
Complement component C6 and C7 haplotypes associated with deficiencies of C6. Ann Hum Genet (1995) 0.83
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc Natl Acad Sci U S A (2001) 2.66
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Immunoglobulin heavy chain genes in humans are located on chromosome. Ann Hum Genet (1981) 1.85
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Isolation of two strains of West Nile virus during an outbreak in southern Russia, 1999. Emerg Infect Dis (2000) 1.65
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Structural relationship and complement fixing activity of sheep and other ruminant immunoglobulin G subclasses. Nature (1969) 1.57
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42
Studies on the terminal stages of complement lysis. Immunology (1973) 1.40
Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29
Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol (1976) 1.28
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp (1986) 1.28
Allotypes of complement components in man. Transplant Rev (1976) 1.27
Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement. J Infect Dis (1990) 1.26
Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. Emerg Infect Dis (2001) 1.26
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Measles virus receptor on human T lymphocytes. Nature (1975) 1.24
The fractionation of antigen-dependent macrophage migration inhibition and macrophage activation factors from lymph draining a tuberculin reaction. Scand J Immunol (1974) 1.24
Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24
The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol (1993) 1.22
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol (1991) 1.22
Lymphocyte cooperation. Proc R Soc Lond B Biol Sci (1971) 1.21
Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum (1988) 1.21
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. Eur J Immunol (1988) 1.18
Restoration of specific immunological virginity. Nature (1974) 1.16
Consent and confidentiality--where are the limits? An introduction. J Med Ethics (2003) 1.15
Cellular immunity in subacute sclerosing panencephalitis. Proc R Soc Med (1974) 1.14
Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) (1993) 1.13
Lesions due to complement in lipid membranes. Nature (1971) 1.13